, Columnist
Valeant's Turnaround Is Still a Work in Progress
The drugmaker is in better shape than a year ago, but still has a long way to go.
This article is for subscribers only.
Looks like we've got a new candidate for a Valeant Pharmaceuticals International Inc. inflection point.
Valeant reported third-quarter earnings and revenue Tuesday morning that beat (lowered) analyst expectations. And for the second quarter in a row, the company defied analyst expectations by maintaining earnings guidance, despite having divested several assets. Shares jumped 15 percent on the news.